Global Clinical Trials is managing a study in patients with COVID-19 active infection in Russia. GCT has completed site initiation visits, which means all sites are active and recruiting now. January 27th, a day after the final clinical site had been initiated, the first patient was recruited for the study.
“GCT is looking forward to seeing the data from this highly relevant project and pleased with the team’s work reaching the first milestones so quickly,” – said Dr. Eugene Selivra, GCT CEO.
About the study:
This is a Phase II clinical study of the medication which has showed preliminary evidence of efficacy due to its anti-inflammatory action. The drug aims to improve the outcomes of hospitalized patients with COVID-19. Through a rigorous feasibility analysis by GCT clinical team, the sponsor selected 5 clinical sites with the most enrollment potential.